New insider Thermo Fisher Scientific Inc. claimed ownership of 17,379,797 shares (SEC Form 3) (Amendment)
$SNCE
Computer Software: Prepackaged Software
Technology
| FORM 3 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 |
|
|||||||||||||||
1. Name and Address of Reporting Person*
(Street)
|
2. Date of Event Requiring Statement
(Month/Day/Year) 12/08/2021 |
3. Issuer Name and Ticker or Trading Symbol
Science 37 Holdings, Inc. [ SNCE ] |
|||||||||||||
|
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
|
5. If Amendment, Date of Original Filed
(Month/Day/Year) 12/20/2021 |
||||||||||||||
6. Individual or Joint/Group Filing (Check Applicable Line)
| |||||||||||||||
| Table I - Non-Derivative Securities Beneficially Owned | |||
|---|---|---|---|
| 1. Title of Security (Instr. 4) | 2. Amount of Securities Beneficially Owned (Instr. 4) | 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 4. Nature of Indirect Beneficial Ownership (Instr. 5) |
| Common Stock | 17,379,797 | I(1)(2)(3) | See footnote(1)(2) |
|
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) | |||||||
|---|---|---|---|---|---|---|---|
| 1. Title of Derivative Security (Instr. 4) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) | 4. Conversion or Exercise Price of Derivative Security | 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 6. Nature of Indirect Beneficial Ownership (Instr. 5) | ||
| Date Exercisable | Expiration Date | Title | Amount or Number of Shares | ||||
1. Name and Address of Reporting Person*
(Street)
Relationship of Reporting Person(s) to Issuer
| ||||||||||||||||||||||||
1. Name and Address of Reporting Person*
(Street)
Relationship of Reporting Person(s) to Issuer
| ||||||||||||||||||||||||
1. Name and Address of Reporting Person*
(Street)
Relationship of Reporting Person(s) to Issuer
| ||||||||||||||||||||||||
1. Name and Address of Reporting Person*
(Street)
Relationship of Reporting Person(s) to Issuer
| ||||||||||||||||||||||||
1. Name and Address of Reporting Person*
(Street)
Relationship of Reporting Person(s) to Issuer
| ||||||||||||||||||||||||
1. Name and Address of Reporting Person*
(Street)
Relationship of Reporting Person(s) to Issuer
| ||||||||||||||||||||||||
1. Name and Address of Reporting Person*
(Street)
Relationship of Reporting Person(s) to Issuer
| ||||||||||||||||||||||||
1. Name and Address of Reporting Person*
(Street)
Relationship of Reporting Person(s) to Issuer
| ||||||||||||||||||||||||
1. Name and Address of Reporting Person*
(Street)
Relationship of Reporting Person(s) to Issuer
| ||||||||||||||||||||||||
1. Name and Address of Reporting Person*
(Street)
Relationship of Reporting Person(s) to Issuer
|
| Explanation of Responses: |
| 1. These shares of common stock, par value $0.0001 per share, of Science 37 Holdings, Inc. are held of record by Pharmaceutical Product Development, LLC ("Pharma LLC"). Wildcat Acquisition Holdings (UK) Limited ("Wildcat") is the sole member of Pharma LLC; Jaguar Holding Company II ("Jaguar II") is the sole shareholder of Wildcat; Jaguar Holding Company I, LLC ("Jaguar I") is the sole shareholder of Jaguar II; Eagle Holding Company II, LLC ("Eagle II") is the sole member of Jaguar I; PPD, Inc. ("PPD") is the sole member of Eagle II; Thermo Fisher Scientific Powder US Holdings Corp. ("Powder Holdings") is the sole shareholder of PPD; Thermo Fisher Scientific Powder US Holdings Ltd ("US Holdings") is the sole shareholder of Powder Holdings; Thermo Fisher Scientific Powder Holdings II Ltd ("Powder Holdings II") is the sole shareholder of US Holdings. |
| 2. Thermo Fisher Scientific Powder Holdings IV Ltd ("Powder Holdings IV") and Thermo Fisher Scientific Powder Holdings I Ltd ("Powder Holdings I") are the 11.76% shareholder and the 88.24% shareholder, respectively, of Powder Holdings II; Thermo Fisher Scientific Powder Holdings III Ltd ("Powder Holdings III") is the sole shareholder of Powder Holdings IV; Spectra-Physics Holdings USA, LLC ("Spectra-Physics") is the sole shareholder of Powder Holdings I; Fisher Scientific Worldwide Inc. ("Worldwide") is the sole member of Spectra-Physics; Fisher Scientific International LLC ("Scientific International") is the sole shareholder of Worldwide; Scientific International is the sole shareholder of Powder Holdings III; and Thermo Fisher Scientific Inc. is the sole member of Scientific International. By virtue of such relationships, each of the reporting persons may be deemed to have beneficial ownership over such shares of common stock. |
| 3. This report on Form 3 is jointly filed by the reporting persons. Each of the reporting persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein. Disclosure of the information required by this Form was made by Pharma LLC, Wildcat, Jaguar II, Jaguar I, Eagle II and PPD pursuant to PPD, Inc.'s Form 3 filed on October 18, 2021 and Form 3/A filed on November 8, 2021. |
| Remarks: |
| This Form 3/A amends and restates the original Form 3 filed by the reporting persons on December 20, 2021, as amended by the reporting persons on December 27, 2021. This amendment is being filed to include Thermo Fisher Scientific Powder US Holdings Ltd, Thermo Fisher Scientific Powder Holdings I Ltd, Thermo Fisher Scientific Powder Holdings II Ltd, Thermo Fisher Scientific Powder Holdings III Ltd, Thermo Fisher Scientific Powder Holdings IV Ltd, Spectra-Physics Holdings USA LLC, Fisher Scientific Worldwide Inc. and Fisher Scientific International LLC as reporting persons. |
| Thermo Fisher Scientific Inc., /s/ Michael Boxer, Senior Vice President and General Counsel | 03/14/2024 | |
| Thermo Fisher Scientific Powder US Holdings Corp., /s/ Anthony H. Smith, President | 03/14/2024 | |
| Thermo Fisher Scientific Powder US Holdings Ltd, /s/ Anthony H. Smith, Director | 03/14/2024 | |
| Thermo Fisher Scientific Powder Holdings IV Ltd, /s/ Anthony H. Smith, Director | 03/14/2024 | |
| Thermo Fisher Scientific Powder Holdings III Ltd, /s/ Anthony H. Smith, Director | 03/14/2024 | |
| Thermo Fisher Scientific Powder Holdings II Ltd, /s/ Anthony H. Smith, Director | 03/14/2024 | |
| Thermo Fisher Scientific Powder Holdings I Ltd, /s/ Anthony H. Smith, Director | 03/14/2024 | |
| Spectra-Physics Holdings USA, LLC, /s/ Anthony H. Smith, Treasurer and Assistant Secretary | 03/14/2024 | |
| Fisher Scientific Worldwide Inc., /s/ Anthony H. Smith, Treasurer and Assistant Secretary | 03/14/2024 | |
| Fisher Scientific International LLC, /s/ Anthony H. Smith, Vice President and Treasurer | 03/14/2024 | |
| ** Signature of Reporting Person | Date | |
| Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. | ||
| * If the form is filed by more than one reporting person, see Instruction 5 (b)(v). | ||
| ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). | ||
| Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. | ||
| Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number. | ||